Literature DB >> 2449299

Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.

C L Lucore1, B E Sobel.   

Abstract

To delineate interactions of infused tissue-type plasminogen activator (t-PA) with inhibitors in plasma and their impact on fibrinolytic activity, serial plasma samples from patients with acute myocardial infarction and from normal rabbits given infusions of t-PA were assayed for t-PA antigen, activity of "fast acting" plasminogen activator inhibitor (PAI-1), and the presence and nature of t-PA-inhibitor complexes. In patients, endogenous t-PA circulated predominantly as a 100 kilodalton (kDa) complex with PAI-1, as verified by immunoprecipitation. During infusions, t-PA circulated not only as free t-PA (55 kDa) but also in complexes with PAI-1 (100 kDa), alpha 2-antiplasmin (110 kDa), and C1-esterase inhibitor (170 kDa). After termination of infusions, levels of free t-PA declined, while inhibitor complexes remained prominent. Free PAI-1 activity, assayed spectrophotometrically, was markedly elevated in the 24 hr interval after infusion of t-PA in 47% of patients with infarction. The specific activity of t-PA during infusions was 0.4 IU/ng or greater. However, during the 3 hr interval after infusions in patients, specific activity declined in association with prominence of t-PA complexes, predominantly with PAI-1. Infusions of t-PA in normal rabbits did not result in reactive increases in PAI-1 activity or in the t-PA-PAI-1 complex. After infusions, t-PA was associated predominantly with alpha 2-antiplasmin and C1-esterase inhibitor rather than PAI-1. t-PA inhibitor complexes were seen despite immediate acidification of whole blood, indicating that they were present in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449299     DOI: 10.1161/01.cir.77.3.660

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

1.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

2.  Kinetics of the reaction of streptokinase-plasmin complex with purified human and mouse alpha 2-macroglobulin. Implications for mechanism.

Authors:  P K Anonick; W H Vetter; S L Gonias
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

3.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.

Authors:  E L Madison; E J Goldsmith; R D Gerard; M J Gething; J F Sambrook; R S Bassel-Duby
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

4.  Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor.

Authors:  W E Hopkins; D R Westerhausen; B E Sobel; J J Billadello
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.

Authors:  D J Schneider; B E Sobel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 7.  Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.

Authors:  Paul Tanswell; Nishit Modi; Dan Combs; Thierry Danays
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.

Authors:  S J McAuliffe; J A Moors; H B Jones
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

9.  Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.

Authors:  R P Gray; J S Yudkin; D L Patterson
Journal:  Br Heart J       Date:  1993-03

10.  Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension.

Authors:  Salvatore Paterna; Vincenzo Di Garbo; Gino Avellone; Pietro Di Pasquale; Antonina Cacia; Antonio Tuttolomondo; Giuseppe Follone; Antonietta Cardinale; Tiziana Maniscalchi; Giuseppe Licata
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.